SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tobira Therapeutics, Inc. (NASDAQ:TBRA) today announced that company management will present an overview of the company at the following conferences in September.
Rodman & Renshaw 18th Annual Global Investment
- Presentation date: Tuesday September 13, 2016
- Presentation time: 2:55 p.m. ET
Aegis Capital Corp 2016 Growth Conference
- Presentation date: Wednesday, September 21, 2016
- Presentation time: 2:30 p.m. PT
A live webcast and 30-day archive of these presentations will be available at http://ir.tobiratx.com.
About Tobira Therapeutics
Tobira is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases. The company's lead product candidate, cenicriviroc (CVC), is a first-in-class immunomodulator and dual inhibitor of CCR2 and CCR5 in late-stage development for the treatment of NASH, a serious liver disease that can progress to cirrhosis, liver cancer and liver failure. CVC is also being investigated to address primary sclerosing cholangitis (PSC), a disease which causes inflammation and scarring of the bile ducts, eventually leading to serious liver damage. Tobira's pipeline also includes evogliptin, a selective DPP-4 inhibitor, which it plans to develop for NASH in combination with CVC. Learn more about Tobira at www.tobiratx.com.
Tobira® is a registered trademark owned by Tobira Therapeutics, Inc.
©2016 Tobira Therapeutics, Inc. All Rights Reserved.